Skip to main content

Table 5 Recurrence rates according treatment group.

From: Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine

Treatment

Recurrence Rate n/N (%)

RI

11/22 (50%)

RI + RO

6/39 (15.4%)

RI + TA

2/26 (7.7%)

P value

P < 0.01 for RI vs RI + RO

P < 0.01 for RI vs RI + TA

P = NS for RI + RO vs RI + TA

  1. RI: rizatriptan; RO: rofecoxib; TA: tolfenamic acid; n: attacks where recurrence were observed; N: number of treated attacks.
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us